NOTE 7 – INVESTMENTS

The Company holds equity investments in five privately held biotechnology companies that do not have readily determinable fair values. The Company has elected to measure these investments using the measurement alternative under ASC 321, under which the investments are carried at cost, less impairment, if any, and adjusted for changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. These investments were initially recorded at their acquisition-date fair values in connection with the Merger (see Note 4).

As of June 30, 2026, the aggregate carrying amount of these investments was $320,543. During the period from the Closing Date through June 30, 2026, the Company recognized no observable price changes requiring adjustment and no impairment with respect to these investments.